Sigyn's development decisions are guided by two main prerequisites: that a candidate therapy should address a clearly defined limitation in healthcare, and that successful clinical advancement could establish a potential competitive advantage relative to established therapeutic approaches. The company is a developer of dialysis-like therapies to address cardiovascular disease and cancer. The company is exploring strategic alternatives including potential merger and asset sale initiatives as of (March 2026).
Cyborg Score Rationale
The market cap is approximately 6.4M, indicating a micro-cap status with significant capital constraints. The company is in development stage without meaningful revenue. Recent funding in February 2026 consisted of small convertible note rounds ($20K and $21.5K in net proceeds), suggesting difficulty accessing capital. The company failed to execute an uplist to Nasdaq due to regulatory complications involving investor pre-approval requirements.
Top Insights
Company has 2,330,042 shares outstanding as of March 2026, reflecting significant dilution risk
Stock is quoted on OTCQB market with discussed efforts to meet Nasdaq Capital Market listing requirements, indicating failed uplist attempts
CEO Jim Joyce previously founded Aethlon Medical where he developed the HemopurifierTM, the first therapy to receive FDA Breakthrough Device designations, bringing relevant expertise
Company is exploring merger and asset sale alternatives as of (March 2026), suggesting strategic reassessment
Named Competitors
Hemopurifier — Extracorporeal blood purification for viral infections and sepsis
ECMO Systems — Extracorporeal membrane oxygenation for critical care support
Sepsis Therapeutic Agents — Conventional pharmacological approaches to sepsis management
Recent Developments
(February 2026) Completed convertible note financing rounds totaling approximately $41.5K in net proceeds
(March 2026) Issued shareholder update regarding potential merger and asset sale initiatives
(January 2026) Announced advancement of CardioDialysis technology and new corporate initiatives
Open the full interactive Sigyn Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.